Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720096 · ClinicalTrials.gov registry record · NA
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT00720096 is a NA study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 4 participants.
The verdict
NCT00720096, a NA study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This pilot study will help us to determine the success of using a special technique called microarray technology to examine cancer genes in order to predict how individual women will respond to one of two therapies, liposomal doxorubicin or topotecan, and which will be more effective in treating ovarian cancer that has returned (recurrent ovarian cancer). We believe that this study may lead to a means by which microarray technology can predict the most effective treatment decision, based on the genetic characteristics of her tumor tissue, for a woman with recurrent ovarian cancer. Another purpose of this study is to determine how quickly a woman with recurrent ovarian cancer will respond to treatment (treatment response rate) and to evaluate the accuracy of the genomic predictions. Recent data suggest that microarray technology can predict a patient's response to chemotherapy; this has not yet been proven in a forward-looking study which is why we are conducting this research.
Interventions
- DRUG Topotecan
- DRUG Liposomal Doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00720096
The ClinicalTrials.gov registry entry for NCT00720096 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Topotecan is the first listed.
NCT00720096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00720096 about?
NCT00720096 is a clinical study titled "Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan". This pilot study will help us to determine the success of using a special technique called microarray technology to examine cancer genes in order to predict how individual women will respond to one of two therapies, liposomal doxorubicin or topotecan, and which will be more effective in treating ova...
What is the current status of trial NCT00720096?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2008-07. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00720096?
The interventions under investigation include: Topotecan (DRUG), Liposomal Doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00720096?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.